<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906695</url>
  </required_header>
  <id_info>
    <org_study_id>393-102-00002</org_study_id>
    <nct_id>NCT03906695</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes</brief_title>
  <official_title>A Multicenter, Open-label, Dose-escalation, Phase 1 Trial to Investigate the Tolerability and Safety of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the tolerability and safety of ASTX727 in Japanese subjects with lower-risk
      MDS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>28days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Pre-dose, 15 min, 30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h after dosing</time_frame>
    <description>pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose, 15 min, 30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h after dosing</time_frame>
    <description>pharmacokinetics parameter</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lower-risk Myelodysplastic</condition>
  <arm_group>
    <arm_group_label>10-Day Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10-Day Schedule
Investigational Medicinal Products (IMP) will be administered for 10 days in total per 4 weeks, i.e. a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-Day Schedule A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-Day Schedule A
IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-Day Schedule B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-Day Schedule B
IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-Day Schedule C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-Day Schedule C
IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7-Day Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7-Day Schedule
IMP will be administered for 7 days in total per 4 weeks, i.e. a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASTX727</intervention_name>
    <description>oral decitabine 5mg + cedazuridine</description>
    <arm_group_label>10-Day Schedule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASTX727</intervention_name>
    <description>oral decitabine 5mg + cedazuridine</description>
    <arm_group_label>5-Day Schedule A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASTX727</intervention_name>
    <description>oral decitabine 10mg + cedazuridine</description>
    <arm_group_label>5-Day Schedule B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASTX727</intervention_name>
    <description>oral decitabine 20mg + cedazuridine</description>
    <arm_group_label>5-Day Schedule C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASTX727</intervention_name>
    <description>oral decitabine 10mg + cedazuridine</description>
    <arm_group_label>7-Day Schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Subjects with a definitive diagnosis of MDS and classified as low or Intermediate-1
             risk by the International Prognostic Scoring System (IPSS) risk category

          2. Subjects meeting at least one of the disease-related criteria for Red blood cell (RBC)
             transfusion, hemoglobin (Hb) ,Absolute neutrophil count,Platelet count within 8 weeks
             prior to initial administration of IMP

          3. Subjects with Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or
             1

          4. Adequate hepatic and renal function

          5. Sexually active men with reproductive capacity (except those who have undergone
             bilateral orchidectomy) must agree to use 2 effective contraceptive measures or remain
             abstinent during the trial and for 3 months after final administration of IMP.
             Sexually active women of child-bearing potential must agree to use 2 effective
             contraceptive measures or remain abstinent during the trial and for 6 months after
             final administration of IMP.

          6. Subjects who have provided written informed consent using the form approved by the
             institutional review board

        Key Exclusion Criteria:

          1. Subjects who have received cytokine therapy, immunosuppressant therapy, or
             chemotherapy within 4 weeks prior to initial investigational medicinal product (IMP)
             administration

          2. Subjects who have received any other IMP or privately-imported medicine within 2 weeks
             prior to initial IMP administration

          3. Subjects with deletion 5q who are to be treated with lenalidomide

          4. Subjects with current or previous bone marrow blast percentage of &gt;10%

          5. Subjects with a diagnosis of chronic myelomonocytic leukemia

          6. Subjects with heart disease of New York Heart Association (NYHA) Functional Class 3 or
             4

          7. Subjects with an uncontrolled systemic disease or active uncontrolled infection

          8. Subjects with diabetes mellitus requiring medical treatment

          9. Subjects with a life-threatening illness, medical condition or multiple organ
             dysfunction, or other reason, including laboratory abnormalities, which in the
             investigator's or subinvestigator's opinion could compromise the subject's safety,
             interfere with the absorption or metabolism of IMP, or compromise the integrity of the
             trial outcome

         10. Subjects with prior malignancy

         11. Subjects who test positive for human immunodeficiency virus antibody, hepatitis B
             virus DNA, or hepatitis C virus antibody

         12. Subjects with a history of surgical gastrectomy

         13. Subjects with previous organ transplantation

         14. Subjects with a â‰¥Grade 2 AE attributable to treatment of underlying disease, excluding
             the AEs

         15. Subjects who have undergone an invasive and extensive operation within 2 weeks prior
             to initial IMP administration

         16. Subjects with hypersensitivity to the IMPs or their excipients

         17. Subjects with known significant mental illness or other condition, such as active
             alcohol or other substance abuse or addiction, that in the opinion of the investigator
             or subinvestigator predisposes the subject to high risk of noncompliance with the
             protocol

         18. Female subjects who are pregnant, breast-feeding, or who test positive for pregnancy
             at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Sato</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>December 25, 2019</last_update_submitted>
  <last_update_submitted_qc>December 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

